article = {RGM-2018-2-102}
title = {Safety and efficacy of bone marrow mononuclear cell transplantation in the treatment of decompensated liver cirrhosis}
journal = {International Journal of Regenerative Medicine}
year = {2018}
issn = {2613-5914}
doi = {http://dx.doi.org/10.31487/j.RGM.2018.02.002}
url = {https://www.sciencerepository.org/safety-and-efficacy-of-bone-marrow-mononuclear-cell-transplantation-in-the-treatment-of-decompensated-liver-cirrhosis_RGM-2-102 
author = {Baoquan  Cheng,Tao Zhou,Xianghua Cui,Yangjing  Gao,Zhen Zhou,Zhi Peng,}
keywords = {Bone marrow mononuclear cells, autologous, transplantation, liver cirrhos}
abstract ={Aims: To evaluate the safety and efficacy of autologous bone marrow mononuclear cells (BM-MNCs) in
the treatment of patients with decompensated liver cirrhosis.
Methods: We randomly assigned 34 patients to control (18 cases) and BM-MNCs (16 cases) groups. All
patients in the BM-MNCs group received granulocyte colony-stimulating factor for 3 days and were then
infused with BM-MNCs. We then tested liver function, blood coagulation parameters, Karnofsky
performance status (KPS), and the levels of procollagen IIIN peptide and hyaluronic acid.
Results: Generally, the symptoms of patients in the BM-MNCs group improved significantly compared to
controls. Six months after transplantation, total bilirubin level was 14.94±7.20μmol/L vs
24.50±15.34μmol/L (p=0.045), albumin level was 40.65±4.94g/L vs 34.78±4.92g/L (p=0.000), and
prothrombin time was 10.86±1.18s vs 13.49±1.80s (p=0.002), respectively. KPS significantly improved
when measured one month and six months after BM-MNCs therapy and showed obvious differences
compared to controls. Changes in Child-Pugh score were also statistically significant when measured six
months after therapy (p=0.001). Mean pretreatment serum baseline levels of procollagen IIIN peptide and
hyaluronic acid were significantly lower than those measured one month after therapy (both p<0.05).
Conclusions: Autologous transplantation of BM-MNCs is safe and effective for patients with
decompensated liver cirrhosis and leads to improvements in liver function, hepatic Child-Pugh score and
KPS.}